Article
High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
Clinical lung cancer - 1 Mar 2014
Mochinaga Koji, Tsuchiya Tomoshi, Nagasaki Toshiya, Arai Junichi, Tominaga Tetsuro, Yamasaki Naoya, Matsumoto Keitaro, Miyazaki Takuro, Nanashima Atsushi, Hayashi Tomayoshi, Tsukamoto Kazuhiro, Nagayasu Takeshi
Abstract excerpt
BACKGROUND: It has been shown that 5-fluorouracil (5-FU) sensitivity in patients with non-small-cell lung cancer (NSCLC) is associated with epidermal growth factor receptor (EGFR) mutation status. However, the relationship between dihydropyrimidine dehydrogenase (DPD), a 5-FU degrading enzyme, and EGFR mutation status is unknown. Here, we focus on clinicopathologic factors and in vitro correlations between DPD...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.